PROX1 and carcinoma: Pearson’s Chi-square test revealed a highly statistically significant difference in PROX1 immuno-expression between different tumor sizes (P = 0.000); with large-sized carcinomas (T3 and T4) showing mainly positive PROX1 expression (23 cases, 88.5%), while the small-sized carcinomas (T1 and T2) showed negative expression (13 cases, 68.4%).